CFM
IONS icon

Catalyst Funds Management’s Ionis Pharmaceuticals IONS Stock Holding History

Catalyst Funds Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$8.67K – 1365
2024
Q1 		$8.67K Buy
+200
New +$9.53K ﹤0.01% 907

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Catalyst Funds Management's IONS Position: Q2 2024 in Review

Catalyst Funds Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2024, closing a stake of 200 shares — an estimated $8.67K sold.

Catalyst Funds Management first reported a position in IONS in Q1 2024 and held it in 1 quarter. The position peaked at $8.67K in Q1 2024. 356 funds tracked by Wall St. Rank hold IONS as of Q2 2024.

  • Catalyst Funds Management reported no remaining Ionis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 200 Ionis Pharmaceuticals shares in Q2 2024, an estimated $8.67K.
  • Catalyst Funds Management first reported a position in Ionis Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Ionis Pharmaceuticals position peaked at $8.67K in Q1 2024.
  • 356 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.